Skip to Content
Merck
CN

N1165

Pimonidazole

≥98% (HPLC),  2-nitroimidazole hypoxia marker, powder

Synonym(s):

NSC 380540, PD 126675;, Ro 03-8799;, alpha-((2-Nitroimidazol-1-yl)methyl)-1-piperidineethanol;, alpha-[(2-Nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C11H18N4O3
CAS Number:
70132-50-2
Molecular Weight:
254.29
UNSPSC Code:
12352200
PubChem Substance ID:
329818508
NACRES:
NA.77
MDL number:
MFCD00867974

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pimonidazole, ≥98% (HPLC)

color

yellow

SMILES string

OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O

InChI key

WVWOOAYQYLJEFD-UHFFFAOYSA-N

InChI

1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2

assay

≥98% (HPLC)

form

powder

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker.
Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker. Pimonidazole forms adducts with thiol groups in proteins, peptides and amino acids.
Pimonidazole possesses a nitro group at position 2 and an imidazole ring. Pimonidazole undergoes reduction and is activated in hypoxic cells.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000518586
0000518586
0000455613
0000455613
0000295515

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Esther A Kleibeuker et al.
Oncotarget, 7(47), 76613-76627 (2016-10-27)
The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have shown benefit of combining RTx with drugs that inhibit tumor blood vessel growth, i.e. angiostatic therapy. Recent findings
Yuhki Koike et al.
Nature communications, 11(1), 4950-4950 (2020-10-04)
Necrotizing enterocolitis (NEC) is a devastating disease of premature infants with high mortality rate, indicating the need for precision treatment. NEC is characterized by intestinal inflammation and ischemia, as well derangements in intestinal microcirculation. Remote ischemic conditioning (RIC) has emerged
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Hanneke Stegeman et al.
Head & neck, 36(9), 1288-1295 (2014-03-29)
Hypoxia, metabolism, and growth factor signaling are important prognostic features in most solid tumors. The purpose of this study was to determine whether head and neck squamous cell carcinoma (HNSCC) xenografts show similar biological and molecular characteristics as the primary
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service